THE rising use of GLP-1 weight-loss drugs in Malaysia, including semaglutide (Ozempic) and tirzepatide (Mounjaro), has highlighted gaps between regulation and enforcement, with authorities continuing to uncover illegal online sales and social-media promotions.
